Angeles Wealth Management LLC Purchases Shares of 2,168 Gilead Sciences, Inc. (NASDAQ:GILD)

Angeles Wealth Management LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,168 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.

Several other hedge funds have also added to or reduced their stakes in the business. Stone Summit Wealth LLC lifted its holdings in Gilead Sciences by 6.3% during the 4th quarter. Stone Summit Wealth LLC now owns 30,503 shares of the biopharmaceutical company’s stock valued at $2,818,000 after purchasing an additional 1,798 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $33,000. Kestra Private Wealth Services LLC lifted its holdings in shares of Gilead Sciences by 4.4% during the fourth quarter. Kestra Private Wealth Services LLC now owns 29,368 shares of the biopharmaceutical company’s stock worth $2,713,000 after buying an additional 1,247 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Gilead Sciences by 55.8% during the fourth quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock worth $20,283,000 after buying an additional 78,657 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Gilead Sciences by 6.8% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 19,933 shares of the biopharmaceutical company’s stock worth $1,841,000 after buying an additional 1,273 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $95.48 on Tuesday. The business’s 50-day moving average price is $93.04 and its 200-day moving average price is $86.86. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51. The firm has a market capitalization of $118.99 billion, a price-to-earnings ratio of 1,060.89, a PEG ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on GILD shares. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Sanford C. Bernstein began coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Wolfe Research began coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity

In related news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.16% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.